Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Everolimus in 2nd Line ccRCC
NCT06317298Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in clear cell renal cell carcinoma (ccRCC), sponsored by Peking University First Hospital. Started Feb 2024; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06317298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317298.